With reference to the BSE Circular Ref. No. LIST/COMP/01/2019-20 dated 02nd April, 2019, Medi-Caps has informed that in terms of the Company’s Code of Conduct to regulate, monitor and report trading in Company’s Securities by Insiders Framed under SEBI (Prohibition of Insider Trading) Regulations 2015, the Trading Window for dealing in the securities of the Company will remain closed for all Designated Persons, their immediate relatives and all connected persons (as defined in the Code) with effect from 1st July, 2025 for the purpose of consideration of Unaudited Standalone and consolidated Financial Results for the Quarter ended 30th June, 2025. Further the company has informed that it has also complied with the requirements of Securities and Exchange Board of India (SEBI) Circular No. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022 and SEBI/HO/ISD/ISDPoD-2/P/CIR/2023/124 dated July 19, 2023, regarding Trading Window Closure period under Clause 4 of Schedule B read with Regulation 9 of SEBI (Prohibition of Insider Trading) Regulations, 2015 (‘PIT Regulations’) framework for restricting trading by Designated Persons (‘DPs’) by freezing PAN at security level. The Trading Window shall open 48 hours after the Unaudited Standalone and consolidated Financial Results for the Quarter ended 30th June, 2025, become generally available i.e. declaration of these Results to the Stock Exchange. All the Directors, KMP’s, Designated Employees, Connected Persons, Fiduciaries and their immediate relatives are advised not to deal in the securities of the Company either directly or indirectly during the aforesaid period. Further, it has submitted the above said information in XBRL mode (excel template provided by Exchange) along with the submission in PDF mode within prescribed time limit. The date of meeting of the Board of Directors to approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June, 2025 will be intimated in due course.